Amgen Boosts Bid for Onyx to $130 a Share

Aug. 7 (Bloomberg) -- Amgen, the drugmaker in pursuit of Onyx Pharmaceuticals, boosted its offer for the company to $130 a share, according to a person familiar with the matter. Cristina Alesci reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)
Square Rival iZettle Raises $67M From Intel and Zouk
54:27 - Today’s "BWest Byte" is $67 million, for how much iZettle, a Swedish payments startup and rival to Jack Dorsey's Square, has raised from Intel and Zouk. Bloomberg's Matt Miller reports on "Bloomberg West." (Source: Bloomberg)
  • What's Next for Flexible Electronic Technology?
  • Facebook Cracks Down on Video Pirates
  • Deep Dive: Is Market Turmoil Hurting Consumer Sentiment?